GlassScriptPhysician profile
Mary A Skiba
NPI 1093765596
$25,200.21
in general payments reported to CMS, 2019-2025
49 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,328 · 2021: $484 · 2022: $1,064 · 2023: $5,148 · 2024: $3,234 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,869 · Consulting Fee: $3,228 · Honoraria: $1,500 · Travel and Lodging: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,868.58 |
| Consulting Fee | $3,227.50 |
| Honoraria | $1,500.00 |
| Travel and Lodging | $1,244.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $9,264.45 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $3,015.09 | 2023-2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $2,882.74 | 2020-2025 | Ultomiris |
| Celgene Corporation | $2,664.15 | 2019-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $1,713.29 | 2019-2025 | Calquence, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,622.69 | 2019-2024 | Opdivo, Reblozyl |
| Glaxosmithkline, LLC. | $374.55 | 2022-2025 | Ojjaara |
| Abbvie INC. | $355.02 | 2019-2025 | Venclexta |
| Incyte Corporation | $293.15 | 2020-2025 | Jakafi, Monjuvi |
| Puma Biotechnology, INC. | $260.93 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $222.90 | 2019-2025 | Keytruda, Welireg, Reblozyl |
| Daiichi Sankyo INC. | $183.77 | 2019-2025 | Vanflyta, Enhertu |
| Astellas Pharma US INC | $178.67 | 2019-2023 | Xtandi |
| Takeda Pharmaceuticals U.S.A., INC. | $172.99 | 2019-2025 | Vonvendi, Advate, Fruzaqla |
| Janssen Biotech, INC. | $161.18 | 2019-2025 | Tecvayli, Talvey |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $157.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $139.93 | 2019-2025 | |
| Verastem, INC. | $132.04 | 2019-2020 | |
| Adc Therapeutics America, INC. | $127.81 | 2024 | |
| Beigene USA, INC. | $98.25 | 2020-2024 | Brukinsa |
| Taiho Oncology, INC. | $88.07 | 2023-2025 | |
| Sobi, INC | $87.74 | 2024-2025 | |
| Amgen INC. | $85.16 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $84.40 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $79.31 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $78.86 | 2024-2025 | Libtayo |
| Tempus Ai, INC | $75.07 | 2024-2025 | Xt Cdx |
| Pharmaessentia USA Corporation | $68.57 | 2024 | Besremi |
| Genmab U.S., INC. | $61.02 | 2023-2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $43.07 | 2019-2023 | Imbruvica |
| Genzyme Corporation | $42.51 | 2023-2025 | |
| Genentech USA, INC. | $39.21 | 2019-2025 | Tecentriq |
| Lilly USA, LLC | $36.41 | 2020-2025 | Jaypirca, Verzenio |
| Beone Medicines USA, INC. | $31.59 | 2025 | Brukinsa |
| Seagen INC. | $29.67 | 2019-2023 | Adcetris |
| Eisai INC. | $26.34 | 2025 | |
| Kite Pharma, INC. | $24.61 | 2025 | Yescarta |
| Servier Pharmaceuticals LLC | $23.92 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.49 | 2025 | Pyrukynd |
| Immunocore Limited | $21.00 | 2025 | Kimmtrak |
| Rigel Pharmaceuticals, INC. | $18.33 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Tactile Systems Technology INC | $16.04 | 2025 | Nimbl, Flexitouch Plus |
| Stemline Therapeutics INC. | $15.72 | 2025 | Orserdu |
| Caris Mpi, INC. | $15.22 | 2025 | Mi Cancer Seek |
| Morphosys, US INC. | $14.47 | 2023 | Monjuvi |
| Epizyme, INC. | $14.22 | 2022 | |
| Dova Pharmaceuticals | $12.89 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.78 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Skiba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.